Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.49 |
| ▸ | PDCD1 | Q15116 | 8/20 | 0.48 |
| ▸ | CD274 | Q9NZQ7 | 8/20 | 0.48 |
| ▸ | VSIR | Q9H7M9 | 9/20 | 0.47 |
| ▸ | NOS3 | P29474 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13778412 | 0.85 | CD274 (0.52) | PDCD1CD274VSIRNOS3NOS1 | |
| SCHEMBL13778407 | 0.82 | VSIR (0.49) | SCN8AEPHX2PRMT6PDCD1CD274 | |
| SCHEMBL13778320 | 0.81 | PRMT6 (0.68) | SCN8AEPHX2PRMT6NOS3NOS1 | |
| SCHEMBL13778363 | 0.81 | PRKCI (0.57) | EPHX2PRMT6NOS3NOS1 | |
| SCHEMBL13778408 | 0.80 | SCN8A (0.43) | SCN8AEPHX2PRMT6PDCD1CD274 | |
| SCHEMBL3666546 | 0.77 | PRMT6 (0.48) | SCN8AEPHX2PRMT6PDCD1CD274 | |
| SCHEMBL13778418 | 0.77 | HRH4 (0.46) | SCN8APDCD1CD274NOS3NOS1 | |
| SCHEMBL14492270 | 0.76 | PDCD1 (0.54) | PDCD1CD274VSIR | |
| SCHEMBL13778347 | 0.75 | CDK8 (0.48) | EPHX2PRMT6NOS3NOS1 | |
| SCHEMBL13778428 | 0.75 | PRMT6 (0.44) | PRMT6PDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314112-B2 | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| US-8314112-B2 | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| WO-2009087225-A2 | PYRROLOPYRIMIDINES AND PYRROLOPYRIDINES | NOVARTIS AG (CH) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | ALK, ACVR1, PTPN4 | SCN8A 1735/4885EPHX2 3222/4885PRMT6 1956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.